Relative Replicative Fitness of Human Immunodeficiency Virus Type 1 Mutants Resistant to Enfuvirtide (T-20)
- 1 May 2004
- journal article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 78 (9) , 4628-4637
- https://doi.org/10.1128/jvi.78.9.4628-4637.2004
Abstract
Resistance to enfuvirtide (ENF; T-20), a fusion inhibitor of human immunodeficiency virus type 1 (HIV-1), is conferred by mutations in the first heptad repeat of the gp41 ectodomain. The replicative fitness of recombinant viruses carrying ENF resistance mutations was studied in growth competition assays. ENF resistance mutations, selected in vitro or in vivo, were introduced into the env gene of HIV-1 NL4-3 by site-directed mutagenesis and expressed in HIV-1 recombinants carrying sequence tags in nef . The doubling time of ENF-resistant viruses was highly correlated with decreasing ENF susceptibility ( R 2 = 0.859; P < 0.001). Initial fitness experiments focused on mutants identified by in vitro selection in the presence of ENF (L. T. Rimsky, D. C. Shugars, and T. J. Matthews, J. Virol. 72:986-993, 1998). In the absence of drug, these mutants displayed reduced fitness compared to wild-type virus with a relative order of fitness of wild type > I37T > V38 M > D36S/V38 M; this order was reversed in the presence of ENF. Likewise, recombinant viruses carrying ENF resistance mutations selected in vivo displayed reduced fitness in the absence of ENF with a relative order of wild type > N42T > V38A > N42T/N43K ≈ N42T/N43S > V38A/N42D ≈ V38A/N42T. Fitness and ENF susceptibility were inversely correlated ( r = −0.988; P < 0.001). Similar results were obtained with recombinants expressing molecularly cloned full-length env genes obtained from patient-derived HIV-1 isolates before and after ENF treatment. Further studies are needed to determine whether the reduced fitness of ENF-resistant viruses alters their pathogenicity in vivo.Keywords
This publication has 35 references indexed in Scilit:
- Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South AmericaNew England Journal of Medicine, 2003
- A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapyAIDS, 2003
- Emergence of Resistant Human Immunodeficiency Virus Type 1 in Patients Receiving Fusion Inhibitor (T-20) MonotherapyAntimicrobial Agents and Chemotherapy, 2002
- A Novel Recombinant Marker Virus Assay for Comparing the Relative Fitness of HIV-1 Reverse Transcriptase VariantsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
- A Novel Recombinant Marker Virus Assay for Comparing the Relative Fitness of HIV-1 Reverse Transcriptase VariantsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
- Virologic and Immunologic Consequences of Discontinuing Combination Antiretroviral-Drug Therapy in HIV-Infected Patients with Detectable ViremiaNew England Journal of Medicine, 2001
- Evidence That the Transition of HIV-1 Gp41 into a Six-Helix Bundle, Not the Bundle Configuration, Induces Membrane FusionThe Journal of cell biology, 2000
- Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection.Proceedings of the National Academy of Sciences, 1994
- A Cross-Sectional Comparison of Persons with Syncytium- and Non-Syncytium-Inducing Human Immunodeficiency VirusThe Journal of Infectious Diseases, 1993
- Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working GroupAntimicrobial Agents and Chemotherapy, 1993